Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Biosimilars: Still Not Quite Ready for Prime Time.

Literature DB >> 27313434

Biosimilars: Still Not Quite Ready for Prime Time.

Abstract

Biosimilars represent a potential savings opportunity for both payers and patients, but how and when the new agents will be accepted and prescribed is uncertain.

Entities: Species

Keywords: 351(k) application; biologics; biosimilars; health benefits; interchangeable; pharmacy practice; substitution

Year: 2016 PMID： 27313434 PMCID： PMC4894513

Source DB: PubMed Journal: P T ISSN： 1052-1372

11 in total

1. Biosimilars: Implications for health-system pharmacists.

Authors: Steven D Lucio; James G Stevenson; James M Hoffman
Journal: Am J Health Syst Pharm Date: 2013-11-15 Impact factor: 2.637

Review 2. US biosimilar pathway unlikely to be used: developers will opt for a traditional BLA filing.

Authors: Claudia Wiatr
Journal: BioDrugs Date: 2011-02-01 Impact factor: 5.807

3. Formulary Selection Criteria for Biosimilars: Considerations for US Health-System Pharmacists.

Authors: Niesha Griffith; Ali McBride; James G Stevenson; Larry Green
Journal: Hosp Pharm Date: 2014-10

4. Utilizing data consortia to monitor safety and effectiveness of biosimilars and their innovator products.

Authors: Mike Baldziki; Jeff Brown; Hungching Chan; T Craig Cheetham; Thomas Conn; Gregory W Daniel; Mark Hendrickson; Lutz Hilbrich; Ayanna Johnson; Steven B Miller; Tom Moore; Brenda Motheral; Sarah A Priddy; Marsha A Raebel; Gurvaneet Randhawa; Penny Surratt; Cheryl Walraven; T Jeff White; Kevin Bruns; Mary Jo Carden; Charlie Dragovich; Bernadette Eichelberger; Edith Rosato; Todd Sega
Journal: J Manag Care Spec Pharm Date: 2015-01

5. Biosimilar competition in the United States: statutory incentives, payers, and pharmacy benefit managers.

Authors: Benjamin P Falit; Surya C Singh; Troyen A Brennan
Journal: Health Aff (Millwood) Date: 2015-02 Impact factor: 6.301

6. Biosimilar competition: lessons from Europe.

Authors: Henry Grabowski; Rahul Guha; Maria Salgado
Journal: Nat Rev Drug Discov Date: 2014-01-21 Impact factor: 84.694

7. NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives.

Authors: Andrew D Zelenetz; Islah Ahmed; Edward Louis Braud; James D Cross; Nancy Davenport-Ennis; Barry D Dickinson; Steven E Goldberg; Scott Gottlieb; Philip E Johnson; Gary H Lyman; Richard Markus; Ursula A Matulonis; Denise Reinke; Edward C Li; Jessica DeMartino; Jonathan K Larsen; James M Hoffman
Journal: J Natl Compr Canc Netw Date: 2011-09 Impact factor: 11.908

8. The Legal and Regulatory Status of Biosimilars: How Product Naming and State Substitution Laws May Impact the United States Healthcare System.

Authors: Jordan Paradise
Journal: Am J Law Med Date: 2015

Biosimilars: Still Not Quite Ready for Prime Time.

1. Biosimilars: Implications for health-system pharmacists.

Review 2. US biosimilar pathway unlikely to be used: developers will opt for a traditional BLA filing.

3. Formulary Selection Criteria for Biosimilars: Considerations for US Health-System Pharmacists.

4. Utilizing data consortia to monitor safety and effectiveness of biosimilars and their innovator products.

5. Biosimilar competition in the United States: statutory incentives, payers, and pharmacy benefit managers.

6. Biosimilar competition: lessons from Europe.

7. NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives.

8. The Legal and Regulatory Status of Biosimilars: How Product Naming and State Substitution Laws May Impact the United States Healthcare System.

9. From "blockbusters" to "biosimilars": an opportunity for patients, medical specialists and health care providers.

Review 10. Biosimilars 101: considerations for U.S. oncologists in clinical practice.

1. Managing the dose escalation of biologics in an era of cost containment: the need for a rational strategy.

Review 2. The Breakthrough of Biosimilars: A Twist in the Narrative of Biological Therapy.

Review 3. Food and Drug Administration guidances on biosimilars: an update for the gastroenterologist.

Review 4. Integrating Biosimilars Into Oncology Practice: Implications for the Advanced Practitioner.